Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Joaquín Guerra, Guillermo Lerzo et al.|The Lancet|2018

Cited by 1.3k